New treatments for breast cancer, multiple sclerosis, and others make the drugmaker's stock a more compelling buy in 2020.
News & Analysis: Novartis
The results should help the upstart drug to compete with Cosentyx.
Cholesterol-lowering inclisiran could be available in the country as early as 2021.
Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
Patients who inherit life-threatening blood disorders have some important new treatment options.
These companies offer strong growth potential and good dividends for investors prepared to look further afield for profit.
Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.
Here's why the FDA recently approved five new drugs way ahead of schedule.
There’s still a long way to go, but the newcomer is off to a good start.
Understanding why can help you identify the next takeout target.